- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05584111
Oral Administration of STC-15 in Subjects With Advanced Malignancies
January 21, 2024 updated by: STORM Therapeutics LTD
Phase 1 Study to Evaluate the Safety, PK, PD, and Clinical Activity of STC-15, a METTL-3 Inhibitor, in Subjects With Advanced Malignancies
This Phase 1, multi-center, open-label, first-in-human study evaluates multiple ascending daily oral doses of STC-15 in Q3W treatment cycles in a 3+3 cohort design with dose levels determined by a modified Fibonacci algorithm.
The study is designed to systematically assess safety and tolerability, pharmacokinetics, pharmacodynamics and clinical activity of STC-15 in adult subjects with advanced malignancies.
Dose levels for further evaluation in expansion cohorts will be selected based on all available PK, pharmacodynamic, target engagement, efficacy, safety, and tolerability data including long-term safety data beyond dose limiting toxicities (DLTs).
The study may be amended to evaluate STC-15 in combination with a Food and Drug Administration-approved standard of care treatment regimen, which could encompass targeted/chemotherapy, radiation therapy and/or immunotherapy with immune checkpoint blockers.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
66
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Melinda Snyder
- Phone Number: 617-233-4057
- Email: melinda.snyder@stormtherapeutics.com
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85258
- Recruiting
- Honor Health
-
Contact:
- Mei Yu
- Email: myu@honorhealth.com
-
Principal Investigator:
- Justin Moser, MD
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- The University of Texas MD Anderson Cancer Center
-
Contact:
- Jordi Rodon Ahnert, M.D., PhD
- Phone Number: 713-792-5603
-
Principal Investigator:
- Jordi Rodon Ahnert, M.D., PhD
-
San Antonio, Texas, United States, 78229
- Recruiting
- South Texas Accelerated Research Therapeutics
-
Principal Investigator:
- Kyriakos Papadopoulos, MD
-
Contact:
- Isabel Jimenez
- Phone Number: 210-593-5265
- Email: Jimenez@startda.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- > 18 years of age
- Histologic or cytologic confirmation of advanced malignancy that has failed standard of care (SOC) therapy and no further SOC therapy is available or the subject has declined additional SOC therapy
- Adequate organ and marrow function
- ECOG PS of 0 or 1
Key Exclusion Criteria:
- Treatment with any local or systemic antineoplastic therapy within 3 weeks prior to first dose of STC-15
- Major surgery or radiation within the 3 weeks
- Immune-related AEs from immunotherapy that required permanent discontinuation
- Central nervous system (CNS) disease involvement, or prior history of Grade ≥3 drug-related CNS toxicity.
- Active autoimmune disease that has required systemic treatment in the 2 years prior to Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Level 1
30mg capsules, daily administration for 3 week (21 day) cycles
|
STC-15 oral capsules various dosing regimen in 3-week cycles
Other Names:
|
Experimental: Dose Level 2
30mg capsules, MWF administration for 3 week (21 day) cycles
|
STC-15 oral capsules various dosing regimen in 3-week cycles
Other Names:
|
Experimental: Dose Level 3
100mg capsules, MWF administration for 3 week (21 day) cycles
|
STC-15 oral capsules various dosing regimen in 3-week cycles
Other Names:
|
Experimental: Dose Level 4
30mg and 100mg capsules, M-MWF administration for 3 week (21 day) cycles
|
STC-15 oral capsules various dosing regimen in 3-week cycles
Other Names:
|
Experimental: Dose Level 5
30mg and 100mg capsules, M-MWF administration for 3 week (21 day) cycles
|
STC-15 oral capsules various dosing regimen in 3-week cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: Screening through end of treatment, approximately 6 months
|
To evaluate the incidence, severity, and duration of adverse events
|
Screening through end of treatment, approximately 6 months
|
Cmax (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine the Cmax concentration over a dosing interval, systemic clearance, volume of distribution at steady-state (Vss), and accumulation ratio from first dose to steady-state.
|
Screening through Cycle 2 (each cycle is 21 days)
|
Tmax (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine the time to Cmax (Tmax)
|
Screening through Cycle 2 (each cycle is 21 days)
|
Ctrough (PK)
Time Frame: Screening through end of treatment, approximately 6 months
|
To determine observed trough serum concentration (Ctrough)
|
Screening through end of treatment, approximately 6 months
|
Terminal elimination half life (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine the terminal elimination half-life (t½)
|
Screening through Cycle 2 (each cycle is 21 days)
|
AUC (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine AUC in 1 dosing interval
|
Screening through Cycle 2 (each cycle is 21 days)
|
Average concentration (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine the average concentration over a dosing interval
|
Screening through Cycle 2 (each cycle is 21 days)
|
Systemic Clearance (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine the systemic clearance
|
Screening through Cycle 2 (each cycle is 21 days)
|
Volume of distribution at steady-state (PK)
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To determine the volume of distribution at steady-state (Vss)
|
Screening through Cycle 2 (each cycle is 21 days)
|
Accumulation ratio from first dose to steady-state (PK)
Time Frame: Screening through end of treatment, approximately 6 months
|
To determine the accumulation ratio from first dose to steady-state
|
Screening through end of treatment, approximately 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy as measured by RECIST 1.1 (DoR)
Time Frame: Screening through disease progression, approximately 6 months
|
Determine the duration of response (DoR)
|
Screening through disease progression, approximately 6 months
|
Efficacy as measured by RECIST 1.1 (PFS)
Time Frame: Screening through disease progression, approximately 6 months
|
Determine progression-free survival (PFS)/PFS assessed per immune-related response evaluation criteria (iPFS).
|
Screening through disease progression, approximately 6 months
|
Efficacy as measured by RECIST 1.1 (DCR)
Time Frame: Screening through disease progression, approximately 6 months
|
Determine the disease control rate (DCR)
|
Screening through disease progression, approximately 6 months
|
Efficacy as measured by RECIST 1.1 (ORR)
Time Frame: Screening through disease progression, approximately 6 months
|
Determine the objective response rate (ORR)
|
Screening through disease progression, approximately 6 months
|
Recommended Phase 2 Dose (RP2D)
Time Frame: Screening through 90 days after the last dose of STC-15, approximately 9 months
|
determine the RP2D for STC-15
|
Screening through 90 days after the last dose of STC-15, approximately 9 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of m6A modification of mRNA from peripheral blood
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To evaluate the effect of STC-15 on METTL3 enzymatic activity
|
Screening through Cycle 2 (each cycle is 21 days)
|
Assessment of serum cytokines levels
Time Frame: Screening through Cycle 2 (each cycle is 21 days)
|
To evaluate immunologic biomarkers in blood and tumor tissue
|
Screening through Cycle 2 (each cycle is 21 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Josefin Holz, STORM Therapeutics
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 15, 2022
Primary Completion (Estimated)
May 30, 2024
Study Completion (Estimated)
May 30, 2025
Study Registration Dates
First Submitted
September 22, 2022
First Submitted That Met QC Criteria
October 14, 2022
First Posted (Actual)
October 18, 2022
Study Record Updates
Last Update Posted (Actual)
January 23, 2024
Last Update Submitted That Met QC Criteria
January 21, 2024
Last Verified
September 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STC15-22101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on STC-15
-
University of UlmTerminated
-
Groupe Hospitalier de la Rochelle Ré AunisNumaHealth InternationalCompletedCovid19 | SARS-CoV-2 Acute Respiratory DiseaseFrance
-
Arizona State UniversityNational Institutes of Health (NIH); National Center for Complementary and...Completed
-
Mayo ClinicCompleted
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA)Completed
-
University Hospital, Strasbourg, FranceCompletedSurgical Intervention | MinorFrance
-
National Cancer Institute (NCI)CompletedHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Renal Cell Carcinoma | Recurrent Skin Carcinoma | Stage III Renal Cell Cancer | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Non-Small Cell Lung Carcinoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IV... and other conditionsUnited States
-
National Cancer Institute (NCI)Completed
-
Dr. Reddy's Laboratories LimitedCompleted
-
NEURALIS s.a.Active, not recruitingCovid19Belgium, Hungary, Russian Federation, Poland